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Introduction
Parenteral antibiotics are indicated when no ettectix e oral anti—
infectis e exists or when the sen usness of infection mandates a high
and reproducible erum concentration. The treatment of cnous
infections with outpatient parenteral antibiotic therap OPAT has
maior advantages over inpatient infusion, The esperience is less
disruptive to the patient’s life than hospital confinement.’ and by any
standard. the expense is less.h Early success treating chronic
infections, such as osteomvelttis’ and pneumonia associated v ith
cystic fibrosis.2 showed the potential of this format. OPAT was
promoted for a variety of infections’- including brain abscess.
endocarditis.°-’ community acquired pneumonia.’ skin and soft
tissue infections,2 pvelonephritis,° and pelvic milammator dis—
ease<U Much of the OPAT process was removed from direct
physician control°’12 as government regulations restricted physi
cians from utilizing infusion services in which the had ownership
because of a potential conflict of interest, The delivery ot OPAT was
then assumed by home care companies as part of their outpatient
services, similar to fluid replacement. supplemental nutrition, and
pain management,<< As with other home care sers ices the physi
cian was responsible for ordering the medications and for complica
tions and outcome of treatment, hut was not directl involved in
monitoring the quality of care An exception to this general rule
does. however, allow physicians to provide OPAT as a direct
extension of their clinical practice. The material loi this paper is
drawn from this model.
Methods
A retrospective review of all the records ot patients in an infectious
disease practitioners outpatient practice ss ho ss crc treated between
0/91 and I 996 with self directed home infusion of OPAT 55 as
performed. Patients considered for the OPAT pro ram ss crc able to
come to the medical office as needed. and had support at home
should they require assistance with inhision. A\ registered nurse
taught each patient the mechanics of’ elt—infuston in intensive
training sessions. Care of the venous access site, administration and
storage of the antibiotic solutions and recognition of side effects
were reinforced until the patient was comfortable ss oh the process.
The nurse and a physician crc available at all times to respond to
questions or problems. The patients came to the office at least twice
a ss eek for dressine changes. inters al history focusing on infusion
problems and adverse events, and re—snppl ofpremixed antibiotics.
The physician examined the patient at least once a week to assess
their clinical status, review laboratory results, and to make changes
in medications.
Each infectious episode constituted a separate study case, thus the
same patient could he represented multiple times for different
infections. Episodes were censored from the analysis if no data was
available for follow—up (8 episodes). Each treatment episode was a
success when the course of parenteral antibiotics was completed,
even if the patient was switched t oral antibiotics. Treatment
failures resulted in hospitalization of the patient prior to conclusion
of therapy or discontinuation of treatment due to unmanageable
adverse effects.
Adverse effects met the following criteria:
1) Nephrotoxicity: a rise in creatinine of0.5 mg/dL if the pretreat
ment baseline was abnormal or a 0.5 mg/d[. rise above normal
standards.
2) Anemia: hemoglobin decrease ot 2 g!d[. irotu pre-treatmenf
baseline.
3) Diarrhea’. >3 loose stools per day,
4) Eighth nerve toxicity: onset of dizziness or imbalance with the
presence of nystagmus or Rhomherg’s sign.
5i Fever: >100.0 F degrees.
01 Thrombocytopenia: platelet count of <Ii tO.( lOt g/l., or >50
drop if pretreat merit baseline vs as hel w.v lOt 13)00 it/I
/4 Neutropenia: ness onset of a a hire blood cdl count <2.500cm
cm oradropot’r50” from pi’e-tr itmeut baseline ii entr <atus
wac below 2,50t) \VF3C’/crn,
5 i—lc’patic dysfunction: rr’anami nose -\i 9’ olue tsv ee the up
ncr limit of normal or Increasc mom prd-trcitrnent baseline if
Results - Patient Population
During the six-year stuth 1nod, 302 courses of OPAT were
administered to 22 I patients. The median duration of therapy was IS
days. ranging from 3 to 307 days. Two—thirds of the patients were
male and the median age was 40.5 vear. C)ther medical conditions
co—existed in 60% of the 302 treatment episodes including solid
organ transplantation, ac.1uired immune deficiency syndrome
(AIDS), diabetes mellitus, chronic obstructive pulmonary disease
COPD), or cancer of a solid organ, [Table 1.
Results - Clinical Infections
Bacterial infections were treated most oden 76 . [Table 21. Gram-
positive bacteria accounted for 59% of isolates t I $0 of 236).
including S. unreus 38i. S. rpiderinklis 25. Almost lort\ percent
(93/236) of the pathocens were gram—negatis e bacteria: J)S’CiI(/Olliu—
nasaernVino,u was the most) requent pathogen undertreatment 35/
93). Forty-one patients had a polymicrobial infection, [Table 3 [.
Viral infections were treated in 63 episodes. including 39 episodes
of cytomegalovirus infection in patients with a transplanted organ.
Eighteen otherepisodes with ctomegalovirus infection were treated
in patients with AIDS, Other viral infections in patients with AIDS
included six episodes of herpes proetitis or herpes esophagitis.
Patients with AIDS were also treated for fungal esophagitis 4i. and
pneurnocvstis carinii pneumorna 8t. At pical mvcohacterium
pulmonar\ infections not associated with 1-I IV were treated on 5
occasions.
Results - Anti-Infective Medications
Cephalosporins accounted for 49% (152) of the 389 courses of
antibiotics. Vancomvcin was used 48 times against methicillin
resistant staphylococci. Otherantibiotics included aminoglycosides,
ureidopenicillins. imipenem. clindamvcin. and ciprofloxicin Anti—
viral agents utilized were ganciclovir. foscarnet. and acclo ir.
Pentamidine was also administered. [Table 11.
Results - Treatment Outcome
OPAT was successful in 94% )283/302) of the episodes. No lurther
anti-infecti e therapy was necessary in 236 cases: step-down to oral
therapy occurred in the remaining 47. Antibiotics were changed
during treatment in 3 patients because of drug resistance and in 12
patients because of intolerable side effects.
Treatment failed in 19 episodes. Of these. 16 episodes required
hospitalization. Clinical deterioration occurred in nine patients w oh
bacterial infections ) osteoin\ elitis. wound infection. pselonephri—
tis. pelvic abscess, septic bursitis. paratvphoid fes ci’. orchitis. cho
laiieitis.and line sepsiso Five patients were hospitalized forprogres
siofl of HI \ inlection. One patient could not cope ith home
infusion and one patient reqLnred a surgical procedure unrelated to
the infection. Therapy was terminated in 3 patients because the side
effects of drug outweighed the benefit of further treatment: in one
patient pentamidine caused vestihular and renal dysfunction: penta
midine caused hypoglycemic reactions in another patient: and
eanciclovir induced throinboc topenia in the third atient. Oerall,
patents with H 1\ mfection experienced signilicantl hir,her rates of
treatment tailure ‘ 26%compared to the rest if the studx population
(4%.
Table 1.— Co-Morbid Conditions
No Underlying Disease 122 40%
Renal Transolant 56 19
AIDS 31 10
Diabetes Meihtus 20
Chronic Obstructive Pulmonary Disease 14 5
Solid Organ Cancer 16 5%
Heart Transplant 13 4%
Chronic Skin and Soft Tissue Infection 7 2%
Coronary Artery Disease 4 1%
End Stage Renal Disease 4 1
Rheumatoid Arthritis 3 1%
Other 12
Other viciuces: Leukemia. Nephrothass. Per p(rer.ai Vascula’ Disease. Prosthetc
lain, Sweets Synarome Systemic Lupus Eryrnematous, Bone Marrom Trar-sianr
Traumatic Arthritis
Cytomegalovirus 57 19%
Sort and Soft Tissue 42 14%
Lower Respiratory Tract 38 13%
Sept icemia 33 11%
Osteornyelitis 29 10%
Ear, Nose. ard Throat 23 5%
Pyelonephritis 19 6%
Post-Operative Wound 11
Intra-abdominal Abscess 11 4
Septc Arthritis 11 4-.
Endocard:ts 6 2%
Herpes Virus 6 2
Other 16 5%
Table 3.— Microbiology
P aeruginosa 38
Saureus 34
S eprdermid;’s 28
Beef 18
E faecalis 14
Streptococcus sp. 14
S pyogenes 12
Enterobacter sp, 12
K pneumoniae 12
Pseudomonas sp. 9
Bactercides sp. 5
Mycohactena so. 5
Otne’i2 3 oraansTsi 49
Table 4.— Anti-Infective Medications
Cephaiosporins 1.52 39%
GancicIovir 54 14%
Vanoomycin 48 12%
Aminogiycosidea 41 11%
Ureidopenicihins 29 757
Foscarnet 14
imirrerrem 13 3%
Pen tamidine 7
Ac0c.a.’ir 2-
rr
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Table 2.— Clinical Diagnosis of Infection
Other includes: actinmycosis, bacterial menuigitis, chronic bronchitis, diverticulitis,
Lyme disease, mycotic aneurysm, orchitis. prostatitis. graft infection, torulopsis
esophagitis, CMV prophylaxis
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Results - Adverse Events
Quantifiable adverse events were documented in 74/302 episodes
25% >. The most frequently encountered verifiable new findings
included renal dysfunction, drug rash, anemia, diarrhea. vestihular
dysfunction, drug feser and hone marrow depression. [Table 5[. In
addition. I 8% of the patients (55 episodes. complained ofconsiitu—
tional sx mptoms reporting fatigue 20 t. headache l2i. anorexia 5t.
as v eli as nausea) I9i. ‘A eaLness 2t. palpitations Ii. sleepiness ( I
and insomnia I
AIDS as an underl ing condition was associated with a signifi
cantly higher rate of erifiahie adverse events (58%) compared to
patients with transplanted organs (26%) or patients with fl() under
lying disease 19%).
The impact of underlv ing disease upon objective adverse events can
be seen by comparing the treatment of eytomegalovirus infections
with ganeielovir in patients with AIDS and organ transplantation.
The incidence of adverse events was much higher in ganciclovir
treatedpatients with HLV infection, 56% (5/9) compared to 33% (141
43) in patients with organ transplantation receiving the same drug.
Other opportunistic inhetions in patients with AIDS were also
associated with a very high incidence of adverse effects during
treatment (>50%). Adverse events were noted in 4 of 6 patients on
pentamidine ftr pneumocystis carinii pneumonia, 2 of 3 patients on
co-trimoxaxole. 4 of 8 patients on foscarnet, 4 of 6 patients treated
for refractory herpes infection with acyclovir, and 3 of 4 patients
with fungal esophagitis treated with Amphoteriein B.
Adverse events from antibiotics used to treat bacterial infections
were also common and resulted in a change of drug in 10 episodes
but did not necessitate termination of OPAT. The incidence of
adverse events was greatest with imipenem and ureidopenicillins
(>20%), though clinicall significant side effects occurred with
vancomycin ( 19% . cephalosporins (13%). and aminoglycosides
(5%) as well.
Rena Toxicity 21 7%
Drug Rash 18 6%
Anem!a 13 4%
Diarrhea 13 4%
Eighth Nerve Toxicty 11 4%
Fever 9 3%
Thrornbocytopen:a 8 3%
Neutropenia 7 2%
Hepatitis 3 1%
Other S!gnit!cant Adverse Events 15 5%
Table 6.— Adverse Events and Med cation
Pertamdne Co.TrmoxCzDSe I 100%
°oscamec Ganccor,o 4 5 80%
Amphotericin B •3/4 75%
Co-Trimoxazoe 2’3 67%
Pentarriidine 4/6 67%
Acyclovir 4/6 67%
Foscarnet 4/8 50%
imipen.em 5/13 39%
Ganciclovir 16/48 33%
Extended Penici1lins 6/29 21%
Vancornycin 9/48 19%
Cephaiosporins 19/152 13%
Aminogiycosides 2/41 5%
Discussion
OPAT ‘a as sucaessful in 94% of the treatment episodes “a ith an
ads erse en ent rate of 25 . The outi.ome of therap in this paper is
similar to thai pres iousls reported hut not the rate of ads erse en ems
or side effects.. \dn erse en cuts, in earlier publications. ‘a crc consid
ered significant ‘a hen there ‘a as a change in therap : the dose of
antibiotic ‘a as adjusted, or the antibiotic ‘a a”dis6ontinued. \Ioni
Luring organ function tm changes of potemial cliniLal si”nificance
is the standard of practice ‘a hen treating infections in patiLnts ‘a ho
are hospital i,ed and is p1 ohahl more impo t nt in the outpatient
setting ‘a heie face to taLc encounters het’a cell the patient and the
tieating pbs sician or staff nurse are less frequent Quantit in tha
tiologs of ann iecogni,Ld adserse esents epresnts ach’ lIen 0
th Llinician as the lactors 01 druo. underlvin di as , nd aurr nt
inkction can eaah plan a significant rol
As tllustiated in this paper underlyine disease cm has a pro
found impact on the morbidity and outcome of thcrapy. The formal
st ucture of all OPAT progiams must include carcful monitoiin of
thc patient for ads ersc cs nts nd bc tailored to th patient. th ir
tnt cOon, treatment, and underlyin discasc
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